Australia markets closed

Structure Therapeutics Inc. (GPCR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
39.96-3.72 (-8.52%)
At close: 04:00PM EDT
40.10 +0.14 (+0.35%)
Pre-market: 08:01AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.28B
Enterprise value 1.85B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)5.30
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 32.33%
S&P500 52-week change 324.96%
52-week high 375.02
52-week low 325.57
50-day moving average 341.27
200-day moving average 345.99

Share statistics

Avg vol (3-month) 3973.54k
Avg vol (10-day) 31.27M
Shares outstanding 557.05M
Implied shares outstanding 646.39M
Float 8115.43M
% held by insiders 14.56%
% held by institutions 181.30%
Shares short (15 May 2024) 44.11M
Short ratio (15 May 2024) 48.73
Short % of float (15 May 2024) 410.93%
Short % of shares outstanding (15 May 2024) 48.82%
Shares short (prior month 15 Apr 2024) 44.11M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-20.43%
Return on equity (ttm)-29.33%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -114.67M
Net income avi to common (ttm)-97.68M
Diluted EPS (ttm)-2.25
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)436.45M
Total cash per share (mrq)3.12
Total debt (mrq)5.12M
Total debt/equity (mrq)1.19%
Current ratio (mrq)19.05
Book value per share (mrq)9.22

Cash flow statement

Operating cash flow (ttm)-93.26M
Levered free cash flow (ttm)-61.89M